Published in Acta Derm Venereol on January 01, 1974
Cardiac involvement and superior vena caval obstruction in Behçet's disease. Thorax (1978) 0.75
Treatment of cryptococcal meningitis associated with the acquired immunodeficiency syndrome. National Institute of Allergy and Infectious Diseases Mycoses Study Group and AIDS Clinical Trials Group. N Engl J Med (1997) 5.88
Candida glabrata: review of epidemiology, pathogenesis, and clinical disease with comparison to C. albicans. Clin Microbiol Rev (1999) 5.84
Practice guidelines for the treatment of candidiasis. Infectious Diseases Society of America. Clin Infect Dis (2000) 5.73
Practice guidelines for the management of cryptococcal disease. Infectious Diseases Society of America. Clin Infect Dis (2000) 5.53
Urinary tract infection: self-reported incidence and associated costs. Ann Epidemiol (2000) 4.26
Detection of circulating candida enolase by immunoassay in patients with cancer and invasive candidiasis. N Engl J Med (1991) 4.20
Voriconazole versus a regimen of amphotericin B followed by fluconazole for candidaemia in non-neutropenic patients: a randomised non-inferiority trial. Lancet (2005) 4.17
Fungemia caused by Candida species and Torulopsis glabrata in the hospitalized patient: frequency, characteristics, and evaluation of factors influencing outcome. Rev Infect Dis (1989) 4.01
Epidemiology and pathogenesis of recurrent vulvovaginal candidiasis. Am J Obstet Gynecol (1985) 3.97
Emerging role of lactobacilli in the control and maintenance of the vaginal bacterial microflora. Rev Infect Dis (1990) 3.19
In vitro activity of a new pneumocandin antifungal, L-743,872, against azole-susceptible and -resistant Candida species. Antimicrob Agents Chemother (1997) 3.17
Critical role of germ tube formation in the pathogenesis of candidal vaginitis. Infect Immun (1984) 3.07
The vaginal microbiome: new information about genital tract flora using molecular based techniques. BJOG (2011) 2.41
Adherence of Candida albicans to human vaginal and buccal epithelial cells. J Infect Dis (1981) 2.27
Prospective multicenter surveillance study of funguria in hospitalized patients. The National Institute for Allergy and Infectious Diseases (NIAID) Mycoses Study Group. Clin Infect Dis (2000) 2.15
Nosocomial Pseudomonas cepacia infection associated with chlorhexidine contamination. Am J Med (1982) 2.14
A comparison of itraconazole versus fluconazole as maintenance therapy for AIDS-associated cryptococcal meningitis. National Institute of Allergy and Infectious Diseases Mycoses Study Group. Clin Infect Dis (1999) 2.14
Comparison of restriction enzyme analysis and pulsed-field gradient gel electrophoresis as typing systems for Candida albicans. J Clin Microbiol (1991) 2.12
Candida-specific cell-mediated immunity is demonstrable in mice with experimental vaginal candidiasis. Infect Immun (1993) 2.08
Validity of the vaginal gram stain for the diagnosis of bacterial vaginosis. Obstet Gynecol (1996) 2.07
Alopecia associated with fluconazole therapy. Ann Intern Med (1995) 2.05
Immunopathogenesis of recurrent vulvovaginal candidiasis. Clin Microbiol Rev (1996) 1.90
Risk factors for second urinary tract infection among college women. Am J Epidemiol (2000) 1.88
Candida-specific Th1-type responsiveness in mice with experimental vaginal candidiasis. Infect Immun (1993) 1.84
Nosocomial acquisition of Candida albicans: an epidemiologic study. J Infect Dis (1993) 1.81
Recurrent vulvovaginal candidiasis. A prospective study of the efficacy of maintenance ketoconazole therapy. N Engl J Med (1986) 1.81
Liver abscess caused by Streptococcus milleri. Rev Infect Dis (1989) 1.71
Torulopsis glabrata vaginitis: clinical aspects and susceptibility to antifungal agents. Obstet Gynecol (1990) 1.69
Effects of preinduced Candida-specific systemic cell-mediated immunity on experimental vaginal candidiasis. Infect Immun (1994) 1.68
Development and verification of fingerprinting probes for Candida glabrata. Microbiology (1997) 1.67
Vulvovaginal candidiasis--what we do and do not know. Ann Intern Med (1984) 1.67
Management of recurrent vulvovaginal candidiasis with intermittent ketoconazole prophylaxis. Obstet Gynecol (1985) 1.64
Papillon-Lefèvre syndrome: a study of the long-term clinical course of recurrent pyogenic infections and the effects of etretinate treatment. Br J Dermatol (1988) 1.62
Polymorphonuclear leucocyte function in Behçet's disease. J Clin Pathol (1977) 1.59
Weekly fluconazole for the prevention of mucosal candidiasis in women with HIV infection. A randomized, double-blind, placebo-controlled trial. Terry Beirn Community Programs for Clinical Research on AIDS. Ann Intern Med (1997) 1.58
Micafungin: a new echinocandin. Clin Infect Dis (2006) 1.58
Nosocomial Candida glabrata colonization: an epidemiologic study. J Clin Microbiol (1998) 1.57
Circulating CD4 and CD8 T cells have little impact on host defense against experimental vaginal candidiasis. Infect Immun (1995) 1.56
Comparison of restriction enzyme analysis versus pulsed-field gradient gel electrophoresis as a typing system for Torulopsis glabrata and Candida species other than C. albicans. J Clin Microbiol (1993) 1.49
Need for alternative trial designs and evaluation strategies for therapeutic studies of invasive mycoses. Clin Infect Dis (2001) 1.48
Mice immunized by primary vaginal Candida albicans infection develop acquired vaginal mucosal immunity. Infect Immun (1995) 1.48
Experimental chronic vaginal candidosis in rats. Sabouraudia (1985) 1.46
Systemic cell-mediated immune reactivity in women with recurrent vulvovaginal candidiasis. J Infect Dis (1993) 1.45
An immunohistochemical study of p53 protein expression in classical Kaposi's sarcoma. Am J Dermatopathol (1996) 1.42
Epidemiology of recurrent vulvovaginal candidiasis: identification and strain differentiation of Candida albicans. J Infect Dis (1986) 1.42
Bacterial adherence in the pathogenesis of urinary tract infection: a review. Rev Infect Dis (1987) 1.41
An unusual late reaction to Zyderm I injections: a challenge for treatment. Plast Reconstr Surg (1993) 1.39
Clinical, microbiological, and biochemical factors in recurrent bacterial vaginosis. J Clin Microbiol (1992) 1.38
Comparative in vitro activity of antimycotic agents against pathogenic vaginal yeast isolates. J Med Vet Mycol (1994) 1.38
A murine model of Candida glabrata vaginitis. J Infect Dis (1996) 1.35
Growth inhibition of Candida albicans by human vaginal epithelial cells. J Infect Dis (2001) 1.35
Nosocomial acquisition of Candida parapsilosis: an epidemiologic study. Am J Med (1993) 1.31
Bacterial vaginosis: treatment with clindamycin cream versus oral metronidazole. Obstet Gynecol (1992) 1.28
The role of cell-mediated immunity in candidiasis. Trends Microbiol (1994) 1.27
Ketoconazole in the prevention of experimental candidal vaginitis. Antimicrob Agents Chemother (1984) 1.26
Chronic vulvovaginal candidiasis: characteristics of women with Candida albicans, C glabrata and no candida. Genitourin Med (1995) 1.23
Histohogical and direct immunofluorescence study of cutaneous hyperreactivity in Behçet's disease. Br J Dermatol (1976) 1.21
Epidemiology of nosocomial acquisition of Candida lusitaniae. J Clin Microbiol (1992) 1.21
Identification of Candida species by randomly amplified polymorphic DNA fingerprinting of colony lysates. J Clin Microbiol (1997) 1.21
Candida vaginitis: self-reported incidence and associated costs. Sex Transm Dis (2000) 1.19
Syphilitic posterior uveitis: correlative findings and significance. Clin Infect Dis (2001) 1.19
Comparison of ketoconazole, Bay N7133, and Bay L9139 in the treatment of experimental vaginal candidiasis. Antimicrob Agents Chemother (1983) 1.18
Adherence of bacteria to vaginal epithelial cells at various times in the menstrual cycle. Infect Immun (1981) 1.17
Gonococcal penile ulcer. Br J Vener Dis (1970) 1.16
Long-term follow-up of patients with bacterial vaginosis treated with oral metronidazole and topical clindamycin. J Infect Dis (1993) 1.16
Vaginal-associated immunity in women with recurrent vulvovaginal candidiasis: evidence for vaginal Th1-type responses following intravaginal challenge with Candida antigen. J Infect Dis (1997) 1.15
Involvement of veins in Behcet's syndrome. Br J Dermatol (1971) 1.15
Behcet's disease. Presentation of 11 cases and evaluation of treatment. Isr J Med Sci (1967) 1.14
Comparison of itraconazole and ketoconazole in the treatment of experimental candidal vaginitis. Antimicrob Agents Chemother (1984) 1.14
Role of antifungal drug resistance in the pathogenesis of recurrent vulvovaginal candidiasis. J Med Vet Mycol (1997) 1.14
Metronidazole-resistant vaginal trichomoniasis--an emerging problem. N Engl J Med (1999) 1.13
Generalized granuloma annulare: relationship to diabetes mellitus as revealed in 8 cases. Br J Dermatol (1970) 1.13
Polymorphonuclear leukocyte and monocyte chemoattractants produced by human fibroblasts. J Clin Invest (1979) 1.10
Karyotyping of Candida albicans isolates obtained longitudinally in women with recurrent vulvovaginal candidiasis. J Infect Dis (1994) 1.10
Atrichia with papular lesions resulting from a nonsense mutation within the human hairless gene. J Invest Dermatol (1999) 1.08
HLA-DRw4 in pemphigus vulgaris patients in Israel. Tissue Antigens (1980) 1.08
Ulcerative colitis in the South African Bantu. Gut (1970) 1.08
Anticardiolipin antibodies in Behçet's disease. J Dermatol (1990) 1.07
Evolution of vaginal Candida species recovered from human immunodeficiency virus-infected women receiving fluconazole prophylaxis: the emergence of Candida glabrata? Terry Beirn Community Programs for Clinical Research in AIDS (CPCRA). Clin Infect Dis (1999) 1.06
Transmission of uropathogens between sex partners. J Infect Dis (1997) 1.05
Cutaneous hyperreactivity in Behçet's disease. Dermatologica (1973) 1.05
Current debate on the use of antibiotic prophylaxis for caesarean section. BJOG (2011) 1.05
Porokeratotic eccrine ostial and dermal duct nevus. An abnormally keratinizing epidermal invagination or a dilated, porokeratotically plugged acrosyringium and dermal duct? Am J Dermatopathol (1992) 1.04
Evolution of antifungal susceptibility among Candida species isolates recovered from human immunodeficiency virus-infected women receiving fluconazole prophylaxis. Clin Infect Dis (2001) 1.03
Urinary tract infection among women aged 40 to 65: behavioral and sexual risk factors. J Clin Epidemiol (2001) 1.03
Candida-specific systemic cell-mediated immune reactivities in human immunodeficiency virus-positive persons with mucosal candidiasis. J Infect Dis (2000) 1.02
Pancreatic ascites treated by irradiation of pancreas. Br Med J (1971) 1.02
Parvovirus B19 infection in human pregnancy. BJOG (2010) 1.02
High-frequency, in vitro reversible switching of Candida lusitaniae clinical isolates from amphotericin B susceptibility to resistance. Antimicrob Agents Chemother (1999) 1.01
Pellagra as the presenting manifestation of Crohn's disease. Gastroenterology (1982) 1.01
Effects of systemic cell-mediated immunity on vaginal candidiasis in mice resistant and susceptible to Candida albicans infections. Infect Immun (1995) 1.01
Epidemiological study of classic Kaposi's sarcoma: a retrospective review of 125 cases from Northern Israel. J Eur Acad Dermatol Venereol (2000) 1.01
Comparison of bacterial and fungal adherence to vaginal exfoliated epithelial cells and human vaginal epithelial tissue culture cells. Infect Immun (1982) 1.00
In vitro activity of a new pneumocandin antifungal agent, L-733,560 against azole-susceptible and -resistant Candida and Torulopsis species. Antimicrob Agents Chemother (1995) 1.00
Mucosal candidal colonization and candidiasis in women with or at risk for human immunodeficiency virus infection. HIV Epidemiology Research Study (HERS) Group. Clin Infect Dis (1998) 1.00